Electrooxidation potential as a tool in the early screening for new safer clozapine-like analogues

Journal of Medicinal Chemistry

Volumn 44, Issue 5, 2001, Pages 769-776

  Mouithys Mickalad, A ^a   Kauffmann, J M ^b   Petit, C ^b   Bruhwyler, J ^c   Liao, Y ^d   Wikstrom H ^d   Damas, J ^a   Delarge, J ^a   Deby Dupont, G ^a   Geczy J ^c   Liegeois J F ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

^c Therabel Pharma Belgium   (Belgium)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE;

AGRANULOCYTOSIS; ARTICLE; CHEMICAL MODIFICATION; LIPID PEROXIDATION; MULTIVARIATE ANALYSIS; OXIDATION; OXIDATION REDUCTION POTENTIAL; STATISTICAL MODEL; STRUCTURE ANALYSIS;

ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; ELECTRICITY; HORSERADISH PEROXIDASE; LIPID PEROXIDATION; MULTIVARIATE ANALYSIS; OXIDATION-REDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035282629     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000221f     Document Type: Article

References (46)

1. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
2. i values
3. 4 receptors: A new opportunity for research on schizophrenia
4. Dopaminergic approaches to antipsychotic agents
5. JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioural properties
6. New pyridobenzodiazepine derivatives as potential antipsychotics: Synthesis and neurochemical study
7. Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: Synthesis and neurochemical study
8. Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine. Identification of a novel atypical neuroleptic
9. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: Chemistry and pharmacological evaluation
10. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis
11. Mechanism of clozapine-induced agranulocytosis. Current status of research and implications for drug development
12. Aplastic anaemia and remoxipride
13. Aplastic anaemia and remoxipride
14. Idiosyncratic reactions drug reactions: Possible role of reactive metabolites generated by leukocytes
15. Drug-associated agranulocytosis: 20 Years of reporting in the Netherlands (1974-1994)
16. Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis
17. Reactive metabolites and agranulocytosis
18. Structural features associated with reactive metabolite formation in clozapine analogues
19. Peroxidase-catalysed oxidation of different dibenzazepine derivatives
20. Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: Application to antipsychotic drugs
21. One-electron-transfer reactions in biochemical systems: II. The reaction of free radicals formed in the enzymatic oxidation
22. One- and two-electron oxidation of reduced glutathione by peroxidases
23. Microsomal lipid peroxidation
24. Antioxidant properties of clozapine and related neuroleptics
25. Inhibition of lipid peroxidation mediated by indolizines
26. JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena
27. Horseradish peroxidase electrode for phenothiazine analysis
28. Drug-induced aplastic anaemia and agranulocytosis incidence and mechanisms
29. Drug induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors
30. Drugs in the aetiology of agranulocytosis and aplastic anaemia
31. Possible role of free radical formation in drug-induced agranulocytosis
32. Prolongation of clozapine-induced granulocytopenia associated with olanzapine
33. Olanzapine: Hematological reactions
34. Safety of olanzapine
35. Sertindole hydrochloride: A novel antipsychotic medication with a favorable side effect profile
36. The relationship of pharmacology to side effects
37. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study
38. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
39. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine
40. 3- bei der metabolisierung des clozapins im menschlichen körper
41. Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: Implications for fluperlapine-induced agranulocytosis
42. Tentative correlation between the electrochemical oxidation of neuroleptics and their pharmacological properties
43. Comportement électrochimique anodique de neuroleptiques en milieu aqueux et nonaqueux
44. Chemistry of dioxygen